Aclaris Therapeutics, Inc. (ACRS) Downgraded to “Sell” at Zacks Investment Research

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Friday, May 12th.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

A number of other analysts have also commented on the company. Jefferies Group LLC set a $36.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 20th. Guggenheim boosted their target price on Aclaris Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, March 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $39.00.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics (NASDAQ ACRS) traded up 3.70% during trading on Friday, reaching $25.49. The company’s stock had a trading volume of 511,777 shares. The firm’s market cap is $681.42 million. Aclaris Therapeutics has a 52 week low of $17.10 and a 52 week high of $33.25. The stock’s 50 day moving average is $25.32 and its 200-day moving average is $28.29.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.06. On average, equities research analysts forecast that Aclaris Therapeutics will post ($3.11) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/06/17/aclaris-therapeutics-inc-acrs-lowered-to-sell-at-zacks-investment-research-updated-updated-updated.html.

A number of institutional investors have recently bought and sold shares of ACRS. State Street Corp increased its position in Aclaris Therapeutics by 29.2% in the fourth quarter. State Street Corp now owns 170,630 shares of the biotechnology company’s stock valued at $4,631,000 after buying an additional 38,570 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Aclaris Therapeutics during the fourth quarter valued at about $4,739,000. Russell Investments Group Ltd. bought a new stake in Aclaris Therapeutics during the fourth quarter valued at about $1,413,000. Columbus Circle Investors increased its stake in Aclaris Therapeutics by 12.9% in the first quarter. Columbus Circle Investors now owns 180,320 shares of the biotechnology company’s stock valued at $5,377,000 after buying an additional 20,642 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in Aclaris Therapeutics by 0.3% in the first quarter. Rice Hall James & Associates LLC now owns 34,827 shares of the biotechnology company’s stock valued at $1,039,000 after buying an additional 93 shares in the last quarter. Institutional investors and hedge funds own 91.40% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Aclaris Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aclaris Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit